Skip to main content
NewslettersWatchlist

Orasure Tech Inc(OSUR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.26
Day High5.38
Open:5.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why OraSure Technologies Stock Is Jumping Today
Globe Newswire
OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year
Globe Newswire
OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET
Globe Newswire
OraSure’s Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack
Globe Newswire
OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
Globe Newswire
OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire
InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School Testing
Globe Newswire
Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure
Globe Newswire
InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants
Globe Newswire
OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue
Globe Newswire
OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET
Globe Newswire
OraSure Technologies’ Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples
Globe Newswire
OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples
Globe Newswire
OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role
Globe Newswire
OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up
Globe Newswire
OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET
Globe Newswire
InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App
Globe Newswire
OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe
Globe Newswire
InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants
Globe Newswire
OraSure Technologies Announces Actions to Enhance Stockholder Value
Globe Newswire
OraSure Technologies Announces 2022 Annual Meeting Date
Globe Newswire
OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus
Globe Newswire
OraSure Technologies to Present at Upcoming Investor Conferences
Globe Newswire
OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary
Globe Newswire
OraSure Technologies Appoints Two New Members to the Board of Directors
Globe Newswire
OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22
Globe Newswire
U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant Detection
Globe Newswire
OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET
Globe NewsWire
OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver
Globe NewsWire
OraSure Receives $205 Million Procurement Contract for InteliSwab™ from the Defense Logistics Agency to Supply Over-the-Counter (OTC) Kits as Part of National Pandemic Response
Globe NewsWire
OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan
Globe NewsWire
OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business

Profile

OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.